🔗 Share this article

Given that America continues making sweeping adjustments to its vaccine guidelines, one figure has emerged in a surprising turn: Tracy Beth Høeg, an American of Danish descent physician and public health researcher who first made her name by casting doubt on COVID-19 vaccines throughout the pandemic and has focused upon potential fatalities following COVID-19 immunization in her short time at the US Food and Drug Administration (FDA).

Scheduled Shifts to Childhood Vaccine Program

Health officials were set to unveil major changes to the pediatric vaccination calendar in December, bringing the US with the Danish vaccine program, according to reports – a substantial departure that would place the US at odds with a large portion of the world with insufficient data for improved outcomes. This reveal has been postponed until the next year.

Rather than Vinay Prasad, Tracy Beth Høeg is listed to speak at the gathering. She was just designated acting director of the FDA’s drug evaluation center, the fifth individual to lead the center this year.

A Shift at the Agency

This interim role might represent a closer partnership between the drug and biologics centers as Høeg and Prasad solidify control at the agency – and it suggests a renewed priority upon reevaluating already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for discontinuing specific pediatric vaccine recommendations in the US to become more like Denmark's approach, a country with comprehensive healthcare and a citizenry about the population of Wisconsin’s.

So far public appearances, she has kept her attention on immunizations – typically the domain of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Doubts Over Qualifications

Høeg has no obvious track record in drug development, oversight or administrative roles, which has been standard for past heads of the CBER. She has worked at the FDA as a senior adviser to the agency head and CBER since earlier this year.

“It seems she lacks to have the requisite experience” for running the drug-regulation department, remarked Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in running a major agency. She has no expertise in industry regulation.”

Former commissioners of the center would “be deeply familiar with regulatory frameworks and the underlying principles of drug development”, said a former acting FDA commissioner. “Frankly, she has not acquired the type of experience that prior appointees who ran the center have had.”

CDER has an immense portfolio at the agency, the former commissioner stated.

“Everybody just focuses on the novel medication approvals, but the generic program clears thousands of generic medications. There’s a biologic copycat branch, OTC medication office and other areas, and every single one must be supervised,” Woodcock said. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Additionally, a substantial administrative aspect to the role, which oversees in excess of 5,000 employees. “It is a enormous administrative position, if you execute it properly,” she said.

Response and Controversial Programs

In response to inquiries about Dr. Høeg's qualifications and whether this appointment signifies greater collaboration among FDA leaders on immunizations, a spokesperson said that the “concerns stem from inaccurate premises”.

“Her resume aligns with the functions of her role,” the official stated, pointing to the period Dr. Høeg spent guiding the agency head on “drug safety and regulatory science, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's controversial expedited review system, a disputed one-day medication authorization process that apparently troubled her predecessors. “By what process are these therapies being chosen for this voucher program? Who makes the calls?” Howard said. “There is a lot of confidentiality going on at the FDA right now.”

In general, he said, “the Food and Drug Administration appears to be shifting towards more relaxed regulations of all drugs, aside from vaccines.”

Public Track Record on Immunizations

Concerning vaccines, Høeg has a clearer, if troubling, past, Howard observe. She published a study using unverified public submissions to determine the incidence of heart inflammation following COVID-19 vaccination. She advised the state of Florida chief medical officer Joseph Ladapo, who was said to have altered data to indicate Covid vaccines are pose a greater threat than they are.

Among her “wish list” for the incoming federal leadership included changing regulations for new vaccines and ending “optional” immunizations, she remarked after the election on a audio program. At the agency, Høeg has reportedly suggested excluding young men from getting COVID-19 vaccinations.

“She is an all-around dogmatist who begins with her conclusions and works backwards to fit the data in a very misleading, fraudulent way,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Høeg aligned with other contrarians, {like|